CLDF Title
Home | Contact Us | Bookmark
MASH HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
Embassy of Education
Webcasts Abstract Library LiverQ Academy National Conference Regional Conferences
 
Back  
 
Reuters Health Information (2007-09-04): Hepatoma-derived growth factor predicts GI tumor outcome

Clinical

Hepatoma-derived growth factor predicts GI tumor outcome

Last Updated: 2007-09-04 19:09:04 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Expression of hepatoma-derived growth factor is elevated in high-risk gastrointestinal stromal tumors, Taiwanese researchers report in the September 1st issue of the International Journal of Cancer.

"Furthermore," senior investigator Dr. Tsung Hui-Hu told Reuters Health, "increased nuclear hepatoma-derived growth factor levels correlated with the proliferating states of high-risk gastrointestinal stromal tumors and predicted poor prognosis for patients with high-risk gastrointestinal stromal tumors after surgery."

Dr. Hu of Chang Gung University College of Medicine, Kaohsiung Hsien and colleagues studied 178 surgically resected CD117-positive high-risk gastrointestinal stromal tumors.

The team found hepatoma-derived growth factor immunoreactivity in both the nucleus and cytoplasm of high-risk gastrointestinal stromal tissue and a positive correlation between these findings and tumor size and tumor mitosis.

There also was a relationship between hepatoma-derived growth factor levels and the established markers of poor prognosis, Ki-67 and proliferating cell nuclear antigen.

Patients with higher hepatoma-derived growth factor levels were significantly more likely to have earlier tumor recurrence and an unfavorable outcome.

The researchers conclude that measures based on hepatoma-derived growth factor provide "an independent prognostic factor" for disease free and overall survival of these patients following surgery.

"These findings support hepatoma-derived growth factor as a candidate gene for development of diagnostic and therapeutic strategies for high-risk gastrointestinal stromal tumors," they add.

Int J Cancer 2007;121:1059-1065.

 
 
 
 

Subscribe

Be the first to know about our latest upcoming programs and events!

CLDF

Follow us

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2025 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.